Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. 1979

R D Sontheimer, and J R Thomas, and J N Gilliam

We have characterized the clinical and laboratory features of 27 patients who had in common a recurring, superficial, nonscarring type of cutaneous lupus erythematosus (LE) that occurred in a characteristic distribution (subacute cutaneous lupus erythematosus [SCLE]). This clinically distinct form of cutaneous LE has not previously been analyzed as a separate entity and thus, its clinical importance has not been fully appreciated. We found that these patients frequently had a mild systemic illness marked by musculoskeletal complaints and serologic abnormalities. Forty-eight percent had systemic LE by American Rheumatism Association criteria; however, none had serious CNS or renal disease. Thus, those with SCLE are a subset of patients with LE who generally have an illness intermediate in severity between discoid LE and severe systemic LE.

UI MeSH Term Description Entries
D008179 Lupus Erythematosus, Discoid A chronic form of cutaneous lupus erythematosus (LUPUS ERYTHEMATOSUS, CUTANEOUS) in which the skin lesions mimic those of the systemic form but in which systemic signs are rare. It is characterized by the presence of discoid skin plaques showing varying degrees of edema, erythema, scaliness, follicular plugging, and skin atrophy. Lesions are surrounded by an elevated erythematous border. The condition typically involves the face and scalp, but widespread dissemination may occur. Lupus Erythematosus, Chronic Cutaneous,Lupus Erythematosus, Cutaneous, Chronic,Discoid Lupus Erythematosus
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D005069 Evaluation Studies as Topic Works about studies that determine the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. Critique,Evaluation Indexes,Evaluation Methodology,Evaluation Report,Evaluation Research,Methodology, Evaluation,Pre-Post Tests,Qualitative Evaluation,Quantitative Evaluation,Theoretical Effectiveness,Use-Effectiveness,Critiques,Effectiveness, Theoretical,Evaluation Methodologies,Evaluation Reports,Evaluation, Qualitative,Evaluation, Quantitative,Evaluations, Qualitative,Evaluations, Quantitative,Indexes, Evaluation,Methodologies, Evaluation,Pre Post Tests,Pre-Post Test,Qualitative Evaluations,Quantitative Evaluations,Report, Evaluation,Reports, Evaluation,Research, Evaluation,Test, Pre-Post,Tests, Pre-Post,Use Effectiveness
D005260 Female Females
D005447 Fluocinonide A topical glucocorticoid used in the treatment of ECZEMA. Fluocinolide,Fluocinolone Acetonide 21-Acetate,Fluocinonide FAPG,Klariderm,Lidemol,Lidex,Lyderm,Metosyn,Novoter,Tiamol,Topsym,Topsyn,Topsyne,Acetonide 21-Acetate, Fluocinolone,FAPG, Fluocinonide,Fluocinolone Acetonide 21 Acetate
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R D Sontheimer, and J R Thomas, and J N Gilliam
March 1982, Clinical and experimental dermatology,
R D Sontheimer, and J R Thomas, and J N Gilliam
January 1996, The British journal of dermatology,
R D Sontheimer, and J R Thomas, and J N Gilliam
March 2001, The British journal of dermatology,
R D Sontheimer, and J R Thomas, and J N Gilliam
November 1982, Annals of internal medicine,
R D Sontheimer, and J R Thomas, and J N Gilliam
July 2009, Lupus,
R D Sontheimer, and J R Thomas, and J N Gilliam
November 1981, Clinical and experimental dermatology,
R D Sontheimer, and J R Thomas, and J N Gilliam
February 2008, La Revue du praticien,
R D Sontheimer, and J R Thomas, and J N Gilliam
December 1985, Harefuah,
R D Sontheimer, and J R Thomas, and J N Gilliam
April 2017, Journal of the Royal Army Medical Corps,
R D Sontheimer, and J R Thomas, and J N Gilliam
July 2000, Presse medicale (Paris, France : 1983),
Copied contents to your clipboard!